- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibiting PCSK9 — biology beyond LDL control
Authors
Keywords
-
Journal
Nature Reviews Endocrinology
Volume 15, Issue 1, Pages 52-62
Publisher
Springer Nature
Online
2018-10-26
DOI
10.1038/s41574-018-0110-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1
- (2018) Kausik K. Ray et al. CIRCULATION
- PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate
- (2018) Mikaël Croyal et al. CLINICAL SCIENCE
- Poststatin era in atherosclerosis management
- (2018) Laurent Yvan-Charvet et al. CURRENT OPINION IN LIPIDOLOGY
- Transintestinal cholesterol excretion in humans
- (2018) Laurens F. Reeskamp et al. CURRENT OPINION IN LIPIDOLOGY
- Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?
- (2018) Theodosios D. Filippatos et al. CURRENT OPINION IN LIPIDOLOGY
- PCSK9 Concentrations in Cerebrospinal Fluid Are Not Specifically Increased in Alzheimer’s Disease
- (2018) Hélène Courtemanche et al. JOURNAL OF ALZHEIMERS DISEASE
- Hypercholesterolemia induces T cell expansion in humanized immune mice
- (2018) Jonathan D. Proto et al. JOURNAL OF CLINICAL INVESTIGATION
- Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk
- (2018) Benoit J. Arsenault et al. Journal of Clinical Lipidology
- NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis
- (2018) Sotirios Tsimikas et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children
- (2018) Charles Arama et al. PLoS One
- No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data
- (2017) Philip D Harvey et al. EUROPEAN HEART JOURNAL
- Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration
- (2017) Brian A Ference et al. EUROPEAN HEART JOURNAL
- The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response
- (2017) Teik Chye Ooi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: Relationship with glomerular filtration rate and lipid metabolism
- (2017) Marion Morena et al. Journal of Clinical Lipidology
- Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9
- (2017) Jonathan B. Edmiston et al. Journal of Clinical Lipidology
- Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice
- (2017) Jean-Mathieu Berger et al. JOURNAL OF LIPID RESEARCH
- A Test in Context: Lipoprotein(a)
- (2017) Sotirios Tsimikas JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Network analyses identify liver‐specific targets for treating liver diseases
- (2017) Sunjae Lee et al. Molecular Systems Biology
- Cognitive Function in a Randomized Trial of Evolocumab
- (2017) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9
- (2017) Rocco Romagnuolo et al. PLoS One
- Low LDL cholesterol,PCSK9andHMGCRgenetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study
- (2017) Marianne Benn et al. BMJ-British Medical Journal
- PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans
- (2017) Andrea Baragetti et al. European Journal of Preventive Cardiology
- Low LDL cholesterol,PCSK9andHMGCRgenetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study
- (2017) Marianne Benn et al. BMJ-British Medical Journal
- Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9
- (2017) Kazuhiko Kotani et al. Journal of Thoracic Disease
- PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
- (2017) Amand F Schmidt et al. Lancet Diabetes & Endocrinology
- Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor)
- (2017) Aurélie Thedrez et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment
- (2017) Matthew T. Mefford et al. CIRCULATION
- Retrograde cholesterol transport in the human Caco-2/TC7 cell line: a model to study trans-intestinal cholesterol excretion in atherogenic and diabetic dyslipidemia
- (2016) Camille Dugardin et al. ACTA DIABETOLOGICA
- Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia—Brief ReportHighlights
- (2016) Aurélie Thedrez et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms
- (2016) Amirhossein Sahebkar et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated HypercholesterolemiaClinical Perspective
- (2016) Mary E. Haas et al. CIRCULATION
- Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy HumansClinical Perspective
- (2016) Gissette Reyes-Soffer et al. CIRCULATION
- Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein MetabolismClinical Perspective
- (2016) Gerald F. Watts et al. CIRCULATION
- Recycling of Apolipoprotein(a) After PlgRKT-Mediated Endocytosis of Lipoprotein(a)Novelty and Significance
- (2016) Monika Sharma et al. CIRCULATION RESEARCH
- Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer’s Disease
- (2016) Francesca Zimetti et al. JOURNAL OF ALZHEIMERS DISEASE
- PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis
- (2016) Anne Langsted et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis
- (2016) John H. Boyd et al. Journal of Innate Immunity
- PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role
- (2016) Frederick J. Raal et al. JOURNAL OF LIPID RESEARCH
- Interpretation of the evidence for the efficacy and safety of statin therapy
- (2016) Rory Collins et al. LANCET
- Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
- (2016) Brian A. Ference et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential Expression of PCSK9 Modulates Infection, Inflammation, and Coagulation in a Murine Model of Sepsis
- (2016) Dhruva J. Dwivedi et al. SHOCK
- Tumor-Induced Hyperlipidemia Contributes to Tumor Growth
- (2016) Jianfeng Huang et al. Cell Reports
- HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”
- (2016) Payal Kohli et al. Journal of the American Heart Association
- PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFR
- (2016) Kyrill S. Rogacev et al. PLoS One
- Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia
- (2015) Eliano Pio Navarese et al. ANNALS OF INTERNAL MEDICINE
- PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension
- (2015) Jean-Mathieu Berger et al. ATHEROSCLEROSIS
- Decreased PCSK9 expression in human hepatocellular carcinoma
- (2015) Mamatha Bhat et al. BMC GASTROENTEROLOGY
- Cross-talk between LOX-1 and PCSK9 in vascular tissues
- (2015) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- Effects of Evolocumab on Vitamin E and Steroid Hormone LevelsNovelty and Significance
- (2015) Dirk J. Blom et al. CIRCULATION RESEARCH
- Statins and diabetes risk
- (2015) Jennifer G. Robinson CURRENT OPINION IN LIPIDOLOGY
- Prognostic value of PCSK9 levels in patients with acute coronary syndromes
- (2015) Baris Gencer et al. EUROPEAN HEART JOURNAL
- Association Between Familial Hypercholesterolemia and Prevalence of Type 2 Diabetes Mellitus
- (2015) Joost Besseling et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9
- (2015) Quoc-Tuan Le et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor
- (2015) Rocco Romagnuolo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line
- (2015) Massimiliano Ruscica et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Do Statins Impair Cognition? A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- (2015) Brian R. Ott et al. JOURNAL OF GENERAL INTERNAL MEDICINE
- PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: Evidence for genotype-specific regulation of lipoprotein metabolism
- (2015) Simon H. Bridge et al. JOURNAL OF HEPATOLOGY
- Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice
- (2015) Vikram Ravindra Shende et al. JOURNAL OF LIPID RESEARCH
- Local effects of human PCSK9 on the atherosclerotic lesion
- (2015) Ilaria Giunzioni et al. JOURNAL OF PATHOLOGY
- HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
- (2015) Daniel I Swerdlow et al. LANCET
- GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation
- (2015) Steve Poirier et al. Cell Reports
- Proprotein Convertase Subtilisin/Kexin Type 9 Deficiency Reduces Melanoma Metastasis in Liver
- (2015) Xiaowei Sun et al. NEOPLASIA
- Safety Profile of Subjects Treated to Very Low Low-Density Lipoprotein Cholesterol Levels (
- (2014) Brendan M. Everett et al. AMERICAN JOURNAL OF CARDIOLOGY
- Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)
- (2014) Daniel Gaudet et al. AMERICAN JOURNAL OF CARDIOLOGY
- Elevated Circulating PCSK-9 Concentration in Renal Failure Patients is Corrected by Renal Replacement Therapy
- (2014) Marcin Konarzewski et al. AMERICAN JOURNAL OF NEPHROLOGY
- Intestinal Lipid Handling
- (2014) Alain Veilleux et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease
- (2014) Sha Li et al. ATHEROSCLEROSIS
- Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor–Dependent and –Independent Mechanisms
- (2014) Shirya Rashid et al. CIRCULATION
- PCSK9
- (2014) Nabil G. Seidah et al. CIRCULATION RESEARCH
- Postprandial hypertriglyceridemia as a coronary risk factor
- (2014) Jan Borén et al. CLINICA CHIMICA ACTA
- Preserved adrenal function in fully PCSK9-deficient subject
- (2014) Bertrand Cariou et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol
- (2014) Moumita Ghosh et al. JOURNAL OF LIPID RESEARCH
- Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans
- (2014) Ylva Bonde et al. JOURNAL OF LIPID RESEARCH
- Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
- (2014) Frederick J. Raal et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 is a critical regulator of the innate immune response and septic shock outcome
- (2014) K. R. Walley et al. Science Translational Medicine
- Transintestinal Cholesterol Excretion Is an Active Metabolic Process Modulated by PCSK9 and Statin Involving ABCB1
- (2013) Cédric Le May et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells
- (2013) Emile Levy et al. ATHEROSCLEROSIS
- Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia
- (2013) Evan A. Stein et al. CIRCULATION
- Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk
- (2013) Amit V. Khera et al. CIRCULATION
- Plasma PCSK9 Is a Late Biomarker of Severity in Patients With Severe Trauma Injury
- (2013) Maëlle Le Bras et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Lipoprotein(a): resurrected by genetics
- (2013) F. Kronenberg et al. JOURNAL OF INTERNAL MEDICINE
- Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets
- (2013) Bertrand Cariou et al. Nutrition & Metabolism
- Aortic calcification: Novel insights from familial hypercholesterolemia and potential role for the low-density lipoprotein receptor
- (2012) Daniel Fantus et al. ATHEROSCLEROSIS
- Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia
- (2012) Frederick Raal et al. CIRCULATION
- PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages
- (2012) ZHIHAN TANG et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients
- (2012) David Sullivan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Regulation of Epithelial Sodium Channel Trafficking by Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
- (2012) Vikas Sharotri et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The PCSK9 decade
- (2012) Gilles Lambert et al. JOURNAL OF LIPID RESEARCH
- Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels
- (2012) Clapton S. Dias et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
- (2012) James M. McKenney et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The biology and therapeutic targeting of the proprotein convertases
- (2012) Nabil G. Seidah et al. NATURE REVIEWS DRUG DISCOVERY
- Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
- (2012) Evan A. Stein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
- (2012) Eli M. Roth et al. NEW ENGLAND JOURNAL OF MEDICINE
- SILAC-based quantitative proteomic analysis of gastric cancer secretome
- (2012) Arivusudar Marimuthu et al. Proteomics Clinical Applications
- Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue
- (2011) Anna Roubtsova et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Endogenous Estrogens Lower Plasma PCSK9 and LDL Cholesterol But Not Lp(a) or Bile Acid Synthesis in Women
- (2011) Lena Persson et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes
- (2011) Budhaditya Mazumdar et al. HEPATOLOGY
- PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke
- (2011) Estelle Rousselet et al. JOURNAL OF LIPID RESEARCH
- Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in Humans
- (2010) Lena Persson et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Increased Secretion of Lipoproteins in Transgenic Mice Expressing Human D374Y PCSK9 Under Physiological Genetic Control
- (2010) Bronwen Herbert et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- HDL and LDL cholesterol significantly influence β-cell function in type 2 diabetes mellitus
- (2010) Janine K Kruit et al. CURRENT OPINION IN LIPIDOLOGY
- Analysis of lipid pathway genes indicates association of sequence variation near SREBF1/TOM1L2/ATPAF2 with dementia risk
- (2010) Chandra A. Reynolds et al. HUMAN MOLECULAR GENETICS
- PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain
- (2010) Mali Liu et al. JOURNAL OF LIPID RESEARCH
- Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters
- (2010) Bin Dong et al. JOURNAL OF LIPID RESEARCH
- PCSK9R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease
- (2010) Marianne Benn et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia
- (2009) Bertrand Cariou et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia
- (2009) Cédric Le May et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- PCSK9 is expressed in pancreatic δ-cells and does not alter insulin secretion
- (2009) Cédric Langhi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Plasma PCSK9 Is Associated with Age, Sex, and Multiple Metabolic Markers in a Population-Based Sample of Children and Adolescents
- (2009) A. Baass et al. CLINICAL CHEMISTRY
- Low- and High-Density Lipoproteins Modulate Function, Apoptosis, and Proliferation of Primary Human and Murine Pancreatic β-Cells
- (2009) Sabine Rütti et al. ENDOCRINOLOGY
- PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities
- (2009) Majambu Mbikay et al. FEBS LETTERS
- PCSK9 impedes hepatitis C virus infectionin vitroand modulates liver CD81 expression
- (2009) Patrick Labonté et al. HEPATOLOGY
- Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation
- (2009) Steve Poirier et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Genetic and Metabolic Determinants of Plasma PCSK9 Levels
- (2009) Susan G. Lakoski et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Vascular Calcifications in Homozygote Familial Hypercholesterolemia
- (2008) Z. Awan et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo
- (2008) Robert J. Schmidt et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Inflammation stimulates the expression of PCSK9
- (2008) Kenneth R. Feingold et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
- (2008) Ahmed Zaid et al. HEPATOLOGY
- Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: A community-based study
- (2008) Chia-Yen Dai et al. JOURNAL OF HEPATOLOGY
- Plasma PCSK9 preferentially reduces liver LDL receptors in mice
- (2008) Aldo Grefhorst et al. JOURNAL OF LIPID RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now